Boston Scientific Corporation $BSX Shares Sold by Robeco Schweiz AG

Robeco Schweiz AG cut its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 20.1% in the 2nd quarter, Holdings Channel reports. The fund owned 82,082 shares of the medical equipment provider’s stock after selling 20,687 shares during the quarter. Robeco Schweiz AG’s holdings in Boston Scientific were worth $8,816,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Sound Income Strategies LLC grew its position in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares during the last quarter. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the 1st quarter worth $26,000. Y.D. More Investments Ltd purchased a new stake in shares of Boston Scientific in the first quarter valued at about $27,000. Princeton Global Asset Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth about $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in Boston Scientific by 72.9% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 145 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 175,782 shares of company stock valued at $17,742,314 over the last quarter. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.9%

Shares of BSX stock opened at $100.94 on Tuesday. The company has a market capitalization of $149.64 billion, a price-to-earnings ratio of 53.98, a PEG ratio of 2.02 and a beta of 0.58. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm has a 50-day moving average price of $100.00 and a 200 day moving average price of $102.52. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the previous year, the business posted $0.63 earnings per share. The company’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on BSX shares. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Raymond James Financial boosted their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a research report on Monday, September 29th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $124.00 price target on shares of Boston Scientific in a research note on Wednesday, October 22nd. Finally, Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $123.77.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.